Theratechnologies Inc T.TH

One possible explanation ... and one for sure price mover ..

[longterm56]

After brainstorming for awhile, I came up with one scenario that might explain why they are so "closed mouths" on an "open trial".  Suppose the data is soooooo good that they don't want to wake up big pharma yet. They may want to get well down the Phase 1 schedule before having to deal with BP nagging at then and their patents. 

I also know of one way to get the share price to rocket ... all I would have to do is sell all my shares.  Not ready to make that sacrifice for you all yet ;)

  -LT

[Wino115]

Wouldn't that (your brainstorm) be nice. I think others here have highlighted that dosage trials focus on a few key things mostly -- the MTD, the RP2D, the safety signals, the pharmacokinetic data (plasma readings, off-target data, interactions, timing signs, etc..) and "some" elements around efficacy.  But we can't forget these are unfortunately patients at the end of their

[palinc2000]

Good post,! Results of a clinical trial and anecdotal results are not the same.I am sure that management is if not  confident at least hopeful that Phase 1 might be successful but the evidence is not there as far as we know,One cannot assume otherwise at the moment